US Stem Cell Inc banner

Company Overview

Business Description

Sector
Health Care
Industry
Biotechnology
Headquarters
United States of America US
IPO date
Feb 19, 2008

U.S.Stem Cell, Inc. is a biotechnology company, which engages in the discovery, development, and subject to regulatory approval, commercialization of autologous cell therapies for the treatment of chronic and acute heart damage. Stem Cell, Inc. is a biotechnology company. The firm is focused on the discovery, development and subject to regulatory approval and commercialization of autologous cell therapies for the treatment of chronic and acute heart damage. Its product candidates are MyoCell, MyoCell SDF-1 and Adipocell. MyoCell and MyoCell SDF-1 product candidates are clinical therapies designed to populate regions of scar tissue within a patient's heart with autologous muscle cells, or cells from a patient's body, for the purpose of improving cardiac function in chronic heart failure patients. The myoblast cells to be injected are gene-modified prior to injection by an adenovirus vector so that they will release extra quantities of stromal derived factor - 1 or SDF-1 protein. The Adipocell product candidate is a cell therapy kit with multiple possible treatment applications using autologous adipose cells. The company is also investigating the use of adipose cells in a variety of clinical applications.

US Stem Cell Inc Investor Relations

Address
1560 Sawgrass Corp Pkwy
Sunrise, Florida
United States of America

Management

Mr. Michael Tomas

CEO, President, CFO & Director

Biography unavailable

Dr. Colleen Robb

Senior Compliance Officer

Biography unavailable

Mr. Phil Posa

Senior Vice President of U.S. & International Sales

Biography unavailable

Ms. Evelyn Flores

Corporate Controller

Biography unavailable

Dr. Sergio Pinski

Medical Director & Member of Scientific Advisory Board

Biography unavailable

1 / 5